| Zacks Company Profile for Rebus Holdings, Inc. (RBSH : OTC) |
|
|
| |
| • Company Description |
| Inspyr Therapeutics, Inc. is a biotechnology company which focuses on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, and other cancers primarily in the United States. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Inspyr Therapeutics, Inc., formerly known as GenSpera, Inc., is based in San Antonio, Texas.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.00 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 29,630 shares |
| Shares Outstanding: 32.13 (millions) |
| Market Capitalization: $0.00 (millions) |
| Beta: -1.52 |
| 52 Week High: $0.00 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
% |
% |
| 12 Week |
% |
% |
| Year To Date |
% |
% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
2629 TOWNSGATE ROAD SUITE 215
-
WESTLAKE VILLAGE,CA 91361
USA |
ph: 818-597-7552
fax: 818-661-6302 |
lcali@inspyrtx.com |
http://www.rebus-corp.com |
|
|
| |
| • General Corporate Information |
Officers
Raul Silvestre - Chief Executive Officer
Scott Ogilvie - Director
Claire Thom - Director
Peter E. Grebow - Director
Bo Jesper Hansen - Director
|
|
Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 75619J103
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding: 32.13
Most Recent Split Date: 10.00 (0.01:1)
Beta: -1.52
Market Capitalization: $0.00 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: - |
|
|
|
| |
